These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 18801635)

  • 21. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    World Health Organization
    World Health Organ Tech Rep Ser; 2005; 929():1-142, backcover. PubMed ID: 16353684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fiftieth report.
    World Health Organ Tech Rep Ser; 2016; (996):1-358, back cover. PubMed ID: 27514184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Equivalence studies for complex active ingredients and dosage forms.
    Bhattycharyya L; Dabbah R; Hauck W; Sheinin E; Yeoman L; Williams R
    AAPS J; 2005 Nov; 7(4):E786-812. PubMed ID: 16594632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Statistical tools for setting in-process acceptance criteria.
    Seely RJ; Munyakazi L; Haury J
    Dev Biol (Basel); 2003; 113():17-25. PubMed ID: 14620848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second report.
    World Health Organ Tech Rep Ser; 1992; 823():1-134. PubMed ID: 1462605
    [No Abstract]   [Full Text] [Related]  

  • 26. Hydrodynamics-induced variability in the USP apparatus II dissolution test.
    Baxter JL; Kukura J; Muzzio FJ
    Int J Pharm; 2005 Mar; 292(1-2):17-28. PubMed ID: 15725550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relations between sales authorisation and pharmacopoeia.
    Cook D
    Ann Ist Super Sanita; 1975; 11(3-4):281-9. PubMed ID: 1234729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The value of USP public standards for therapeutic products.
    Bhattacharyya L; Cecil T; Dabbah R; Roll D; Schuber S; Sheinin EB; Williams RL;
    Pharm Res; 2004 Oct; 21(10):1725-31. PubMed ID: 15553215
    [No Abstract]   [Full Text] [Related]  

  • 29. The USP Performance Verification Test, Part II: collaborative study of USP's Lot P Prednisone Tablets.
    Glasgow M; Dressman S; Brown W; Foster T; Schuber S; Manning RG; Wahab SZ; Williams RL; Hauck WW
    Pharm Res; 2008 May; 25(5):1110-5. PubMed ID: 18172582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Provable Data Integrity in the Pharmaceutical Industry Based on Version Control Systems and the Blockchain.
    Steinwandter V; Herwig C
    PDA J Pharm Sci Technol; 2019; 73(4):373-390. PubMed ID: 30770485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statistical considerations in setting product specifications.
    Dong X; Tsong Y; Shen M
    J Biopharm Stat; 2015; 25(2):280-94. PubMed ID: 25358110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ingredients in pharmaceutical preparations: a problem not value.
    Lubner GC
    Boll Chim Farm; 2002; 141(5):332. PubMed ID: 12481372
    [No Abstract]   [Full Text] [Related]  

  • 33. Estimation of the probability of passing the USP dissolution test.
    Wang H
    J Biopharm Stat; 2007; 17(3):407-13. PubMed ID: 17479390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discriminatory power of the different requirements for uniformity of dosage units in the European pharmacopoeia.
    Limberg J; Savsek M
    Pharmeur Sci Notes; 2006 Dec; 2006(2):45-8. PubMed ID: 17691214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How development and manufacturing will need to be structured--heads of development/manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Nepveux K; Sherlock JP; Futran M; Thien M; Krumme M
    J Pharm Sci; 2015 Mar; 104(3):850-64. PubMed ID: 25630721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reliability and reproducibility of vertical diffusion cells for determining release rates from semisolid dosage forms.
    Hauck WW; Shah VP; Shaw SW; Ueda CT
    Pharm Res; 2007 Nov; 24(11):2018-24. PubMed ID: 17530388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. European Pharmacopoeia (EP), USDA and MAFF standards--will they ever be harmonised under the VICH umbrella?
    Castle P
    Dev Biol (Basel); 2005; 121():227-34. PubMed ID: 15962485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An industry commentary on regulatory issues--microbiology.
    Moldenhauer JE
    PDA J Pharm Sci Technol; 2002; 56(2):60-4. PubMed ID: 11977405
    [No Abstract]   [Full Text] [Related]  

  • 39. International Conference on Harmonisation; guidance on Q4B Evaluation and Recommendation of Pharmacopoeial Texts for use in the International Conference on Harmonisation Regions; Annex 4C on Microbiological Examination of Nonsterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use General Chapter; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Apr; 74(66):15992-3. PubMed ID: 19507323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug standards laboratory enters second decade.
    Reese KM
    J Am Pharm Assoc; 1972 Jan; 12(1):16-20. PubMed ID: 5007258
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.